+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

UK Travel Vaccine Market Forecast to 2028 - COVID-19 Impact and Country Analysis By Product and Application

  • PDF Icon

    Report

  • 122 Pages
  • July 2022
  • Region: United Kingdom
  • The Insight Partners
  • ID: 5646857
UP TO OFF until Jan 15th 2023
The travel vaccine market is expected to grow from US$ 267.56 million in 2021 to US$ 524.88 million by 2028; it is estimated to grow at a CAGR of 10.1% from 2022 to 2028.

Travel vaccines, also called travel immunizations, are shots travelers get before visiting certain areas of the world that help protect them from developing serious illnesses. Vaccinations work by exposing the body to a weakened/dead germ or part of a germ of the disease. These vaccines are recommended to protect against diseases endemic to the country of origin or destination. It is intended to protect travelers and prevent disease spread within or between countries. In many cases, countries require proof of vaccination for travelers wishing to enter or exit the country.

Travelling and tourism have become an integral part of the human lifestyle. It has added a change in the ongoing routine of people and offered several opportunities to explore different cultures, traditions, spiritualism, rural and ethnic tourism, and wellness and health holidays worldwide. Travelling outside the country requires immunization as a safety and precautionary measure to avoid spreading infections. Various countries have policies to protect their citizens from travel-associated infections. For instance, in the UK, National Health Service (NHS) organizes routine immunization or vaccination schedule for its citizens. If a person travels outside the UK, they must get vaccinated to prevent infectious diseases such as hepatitis A, typhoid, and yellow fever. With ~40 million visitors in 2017, the UK is among the most well-liked foreign travel destinations. Although the UK is renowned for its unpredictable weather, the winters and summers are generally temperate, albeit occasionally damp. The UK recognizes Covaxin as a reliable COVID-19 travel vaccination. This indicates that those immunized with Covaxin, one of the two main COVID-19 vaccines, will not have to separate themselves once they arrive in England. After experiencing a significant annual decline in 2020 due to the COVID-19 pandemic, Statista reports that the number of foreign tourists arriving in Europe increased by ~20% in 2021 compared to 2020.

Based on product, the UK travel vaccines market is segmented into hepatitis A, hepatitis B, meningococcal vaccines, and others. The others segment holds held the largest market share in 2021. However, the meningococcal vaccines segment is expected to register the highest CAGR during the forecast period. The others segment primarily consists of the human papillomavirus vaccine, Zika virus vaccine, DPT (tetanus/diphtheria/pertussis), yellow fever, typhoid, Japanese encephalitis, measles, mumps and rubella, rabies, polio, influenza, varicella and shingles, cholera, and others. Typhoid is caused by Salmonella typhi and is common UK, 21.5 million cases are registered every year with 216,500 deaths every year. Influenza is a common viral infection in Europe, influenza activity appeared to decrease. Influenza A(H3N2) predominated. Cause by Vibrio cholerae, cholera is an acute diarrheal illness which affects 1.3 to 4 million people and causes 21,000-143,000 deaths every year UK. Vaccines protects against the HPV group of more than 200 related viruses. Out of these, 200 related viruses more than 40 are spread through direct sexual contact. Two types of HPV can cause genital warts, while more than 24 types can cause certain types of cancers such as, cervical, anal, oropharyngeal, among others. In the US, three HPV vaccines have been licensed for usage - Gardasil, Gardasil 6, and Cervarix. While travel advisories have no recommendations around HPV vaccinations, travelers of all kind prefer getting vaccinated, especially those who travel regularly to regions with high prevalence of HPV.

Based on application, the travel vaccine market is segmented into domestic travel and outbound travel. In 2021, the outbound travel segment is likely to account for the largest share of the market. The market for this segment is expected to grow at the fastest CAGR of 10.4% during 2021-2028. Outbound travel is the act of traveling outside of the home country for leisure, business, or other purposes. Many people travel internationally for business purposes. The number of visits abroad from the UK dropped sharply in 2020 over the previous year due to the COVID-19 pandemic, then fell further in 2021. That year, holidays accounted for the best outbound visits, with roughly 8.9 million trips made for this purpose. However, the number of vacations abroad only accounted for 15% of the holiday trips made in 2019. Overall, the number of visits abroad from the UK was approximately 19 million in 2021. Spending on trips abroad by residents of the UK increased by 12% in 2021 over the previous year, after dropping sharply in 2020 due to the pandemic. Overall, the outbound tourism expenditure within the UK amounted to roughly US$ 20.7 billion in 2021, rising from US$ 18.73 billion in 2020 but remaining way below pre-pandemic levels. While the outbound expenditure slightly recovered in 2021, the number of visits abroad from the UK declined further compared to the first year of the crisis. In 2022, in a Travel Leaders Group survey, 24% of Americans stated they planned to travel to Europe. Additionally, it is expected that the tourist arrivals are expected to increase steadily in regions such as Asia and Europe.

A few key primary and secondary sources referred to while preparing the report on the travel vaccine market are the World Health Organization (WHO), UK Health Security Agency, and the CDC.


Frequently Asked Questions about the UK Travel Vaccine Market

What is the estimated value of the UK Travel Vaccine Market?

The UK Travel Vaccine Market was estimated to be valued at $267.56 million in 2022.

What is the growth rate of the UK Travel Vaccine Market?

The growth rate of the UK Travel Vaccine Market is 10.1%, with an estimated value of $524.88 million by 2028.

What is the forecasted size of the UK Travel Vaccine Market?

The UK Travel Vaccine Market is estimated to be worth $524.88 million by 2028.

Who are the key companies in the UK Travel Vaccine Market?

Key companies in the UK Travel Vaccine Market include GlaxoSmithKline plc., Merck & Co., Inc., Sanofi, Novartis AG, Pfizer Inc., Dynavax Technologies, Emergent BioSolutions Inc., Abbott and SEQIRUS.

Table of Contents

1. Introduction
1.1 Scope of the Study
1.2 Research Report Guidance
1.3 Market Segmentation
1.3.1 Travel Vaccines Market - By Product
1.3.2 Travel Vaccines Market - By Application
2. Travel Vaccines Market - Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Travel Vaccines Market - Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 UK - PEST Analysis
4.3 Expert Opinion
5. UK Travel Vaccine Market - Key Market Dynamics
5.1 Market Drivers
5.1.1 Increasing Travel and Tourism
5.1.2 Growing Incidences of Infectious Diseases
5.2 Market Restraints
5.2.1 High Cost of Travel Vaccines
5.3 Market Opportunities
5.3.1 Awareness Regarding Vaccines
5.4 Future Trends
5.4.1 Never-ending Demand for Vaccines
5.5 Impact Analysis
6. Travel Vaccines Market - UK Analysis
6.1 UK Travel Vaccines Marker Revenue Forecast and Analysis
6.2 UK Travel Vaccines Market - Forecast and Analysis
6.3 Market Positioning of Key Players
6.4 Comparative Company Analysis
6.5 Growth Strategy Analysis
6.6 Performance of Key Players
6.6.1 GlaxoSmithKline
6.6.2 Sanofi
7. UK Travel Vaccine Market Revenue and Forecasts To 2028 - Product
7.1 Overview
7.2 Travel Vaccines Market Revenue Share, by Product (2021 and 2028)
7.3 Hepatitis A
7.3.1 Overview
7.3.2 Hepatitis A: Travel Vaccines Market- Revenue and Forecast to 2028 (US$ Million)
7.4 Hepatitis B
7.4.1 Overview
7.4.2 Hepatitis B: Travel Vaccines Market- Revenue and Forecast to 2028 (US$ Million)
7.5 Meningococcal Vaccines
7.5.1 Overview
7.5.2 Meningococcal Vaccines: Travel Vaccines Market- Revenue and Forecast to 2028 (US$ Million)
7.6 Others
7.6.1 Overview
7.6.2 Others: Travel Vaccines Market- Revenue and Forecast to 2028 (US$ Million)
8. UK Travel Vaccine Market Revenue and Forecasts To 2028 - Application
8.1 Overview
8.2 Travel Vaccines Market Revenue Share, by Application (2021 and 2028)
8.3 Domestic Travel
8.3.1 Overview
8.3.2 Domestic Travel: Travel Vaccines Market- Revenue and Forecast to 2028 (US$ Million)
8.4 Outbound Travel
8.4.1 Overview
8.4.2 Outbound Travel: Travel Vaccines Market- Revenue and Forecast to 2028 (US$ Million)
9. Travel Vaccines Market Analysis - By Country
9.1 UK: Travel Vaccines Market - Revenue and Forecast to 2028 (US$ Million)
9.1.1 UK: Travel Vaccines Market - Revenue and Forecast to 2028 (US$ Million)
9.1.2 UK: Travel Vaccines Market, by Product, 2019-2028 (US$ Million)
9.1.3 UK: Travel Vaccines Market, by Application, 2019-2028 (US$ Million)
10. Impact Of COVID-19 Pandemic on UK Travel Vaccine Market
10.1 UK: Impact Assessment of COVID-19 Pandemic
11. UK Travel Vaccine Market-Industry Landscape
11.1 Overview
11.2 Growth Strategies in the Travel Vaccines Market, (%)
11.3 Organic Developments
11.3.1 Overview
11.4 Inorganic Developments
11.4.1 Overview
12. Company Profiles
12.1 GlaxoSmithKline plc.
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 Merck & Co., Inc.
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 Sanofi
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 Novartis AG
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 Pfizer Inc.
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 Dynavax Technologies
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 Emergent BioSolutions Inc.
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
12.8 Abbott
12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments
12.9 Valneva SE.
12.9.1 Key Facts
12.9.2 Business Description
12.9.3 Products and Services
12.9.4 Financial Overview
12.9.5 SWOT Analysis
12.9.6 Key Developments
12.10 SEQIRUS
12.10.1 Key Facts
12.10.2 Business Description
12.10.3 Products and Services
12.10.4 Financial Overview
12.10.5 SWOT Analysis
12.10.6 Key Developments
13. Appendix
13.1 About the Publisher
13.2 Glossary of Terms

Companies Mentioned

A selection of companies mentioned in this report includes:

  • GlaxoSmithKline plc.
  • Merck & Co., Inc.
  • Sanofi
  • Novartis AG
  • Pfizer Inc.
  • Dynavax Technologies
  • Emergent BioSolutions Inc.
  • Abbott
  • Valneva SE
  • SEQIRUS